Immune checkpoint inhibitors for refractory childhood cancers

Mené dans 10 pays sur 90 enfants et jeunes adultes atteints d'un lymphome ou d'une tumeur solide réfractaire ou récidivante (âge médian : 14 ans), cet essai de phase I/II analyse les caractéristiques pharmacocinétiques et évalue la toxicité de l'atézolizumab, un inhibiteur de point de contrôle immunitaire ciblant PD-L1

Résumé en anglais

Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte associated protein 4 (CTLA-4), PD-L1, and its receptor PD-1 have shown substantial antitumour activity and received regulatory approval for various adult cancers. However, the clinical development of immune checkpoint inhibitors in children with refractory tumours has lagged behind that in adults, in contrast to adult tumours, few paediatric tumour types have shown objective responses to date